-+ 0.00%
-+ 0.00%
-+ 0.00%
BioArctic Says Five-Year Leqembi Data Show Increasing Benefit in Early Alzheimer’s Disease
Share
Listen to the news
BioArctic Says Five-Year Leqembi Data Show Increasing Benefit in Early Alzheimer’s Disease
  • BioArctic's partner Eisai presented five-year Leqembi results today at Boston's CTAD conference, showing increasing benefit in early Alzheimer's disease.
  • Continuous treatment in the Clarity AD study and its extension slowed cognitive and functional decline compared with matched historical patient data.
  • Patients treated earlier showed greater benefit, with most in the low-tau subgroup improving from baseline following five years of continuous treatment.
  • No new safety findings emerged over five years; treatment-related brain swelling occurred most frequently during the first six months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 202611161805BITN____UKPR__EN_20261116-BIT-9999-0) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending